Announcements

A Form 4 filed with the SEC on August 4, 2026 reports that Richard E. Uihlein, a director and 10% owner of Galectin Therapeutics Inc. (NASDAQ: GALT), converted two series of Line of Credit Convertible Notes into common stock on July 31, 2026, through …

Ball Corporation filed a Current Report on Form 8-K with the SEC on August 4, 2026, disclosing that it issued a press release and would hold a conference call regarding its financial results for the quarter ended June 30, 2026.

Rhythm Pharmaceuticals, Inc. filed a Current Report on Form 8-K on August 4, 2026, disclosing preliminary Phase 2 trial data for RM-718 in patients with acquired hypothalamic obesity and announcing its financial results for the second quarter ended June 30, 2026.

RE/MAX Holdings, Inc. and The Real Brokerage Inc. jointly filed a Rule 425 notice on August 4, 2026, reminding holders of RE/MAX Class A Common Stock of an August 18, 2026 deadline to elect the form of merger consideration they wish to receive in …

Galectin Therapeutics Inc. filed a Form 8-K with the SEC on August 4, 2026, reporting that on July 31, 2026, the company issued 34,376,167 shares of common stock to its Chairman and largest stockholder upon the conversion of all outstanding convertible promissory notes held …

RE/MAX Holdings, Inc. filed a current report with the U.S. Securities and Exchange Commission on August 4, 2026, announcing the deadline for holders of its Class A common stock to elect the form of consideration they wish to receive in connection with the pending …

RE/MAX Holdings, Inc. filed a current report on August 4, 2026, announcing that stockholders of record have until 5:00 p.m. New York City time on August 18, 2026, to elect the form of consideration they wish to receive in connection with the pending acquisition …